Abstract
Allogeneic hematopoietic cell transplantation (AHCT) represents the only curative therapy for many haematological malignancies. The graft-versus-leukemia effect (GVL), driven by donor T-cells plays a major role in its curative potential. This effect is sometimes very evident when AML and MDS relapses post AHCT are treated with donor lymphocyte infusions (DLI).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
